Ocuphire Pharma, Inc.

OCUP

US67577R1023

Pharmaceuticals

Delayed Nasdaq Other stock markets 03:18:34 2024-07-12 pm EDT			5-day change	1st Jan Change
1.94 ^USD	+7.18%		+27.21%	-35.55%

Jul. 01	Ocuphire Pharma, Inc.(NasdaqCM:OCUP) dropped from Russell Microcap Growth Index	CI
Jul. 01	Ocuphire Pharma, Inc.(NasdaqCM:OCUP) dropped from Russell 3000E Growth Index	CI

Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy At Retina Meetings in June

June 06, 2024 at 07:57 am EDT

Ocuphire Pharma, Inc. announced that clinical updates on the Company's lead candidate APX3330 for diabetic retinopathy (DR) will be featured in upcoming presentations at the Clinical Trials at the Summit meeting on June 8 in Park City, Utah, and the Retinal Imaging Biomarkers & Endpoints Summit meeting June 25-27 in Boston. APX3330 is an oral small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein) being developed for the treatment of non-proliferative diabetic retinopathy (NPDR). Ocuphire anticipates initiating the ZETA-2 Phase 2/3 trial of APX3330 for NPDR in early 2025.

Latest news about Ocuphire Pharma, Inc.

Ocuphire Pharma, Inc.(NasdaqCM:OCUP) dropped from Russell Microcap Growth Index	Jun. 30	CI
Ocuphire Pharma, Inc.(NasdaqCM:OCUP) dropped from Russell 3000E Growth Index	Jun. 30	CI
Ocuphire Pharma, Inc.(NasdaqCM:OCUP) added to Russell Microcap Value Index	Jun. 30	CI
Ocuphire Pharma, Inc.(NasdaqCM:OCUP) added to Russell 3000E Value Index	Jun. 30	CI
Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy At Retina Meetings in June	Jun. 06	CI
Ocuphire Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 10	CI
Ocuphire Pharma Enrolls 1st Patient in Phase 3 Trial of Visual Acuity Treatment	Apr. 11	MT
Ocuphire Pharma, Inc. Announces Global License Agreement with Viatris Inc	Apr. 11	CI
Ocuphire Pharma, Inc. Announces the Enrollment of the First Subject in the LYNX-2 Phase 3 registration study	Apr. 11	CI
Alliance Global Partners Cuts Price Target on Ocuphire Pharma to $20 From $24, Maintains Buy Rating	Mar. 20	MT
Ocuphire Pharma, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 08	CI
Ocuphire Pharma Appoints CFO, Science Chief	Feb. 14	MT
Ocuphire Pharma, Inc. Announces Appointments of Ash Jayagopal, Ph.D., M.B.A. as Chief Scientific and Development Officer	Feb. 14	CI
Ocuphire Pharma, Inc. Announces Appointments of Nirav Jhaveri, C.F.A., M.B.A. as Chief Financial Officer	Feb. 14	CI
Ocuphire Pharma, Inc. Announces Presentation of Clinical Data from Its ZETA-1 Trial on A Person-Level Scale Evaluating APX3330 in Diabetic Retinopathy	Feb. 05	CI
Ocuphire Pharma, Inc. Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity Under Dim Light Conditions	Jan. 04	CI
Ocuphire Pharma, Inc. Promotes Ronil Patel to Chief Business Officer, Effective as of December 1, 2023	Dec. 06	CI
Transcript : Ocuphire Pharma, Inc., Q3 2023 Earnings Call, Dec 05, 2023	Dec. 05
Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer	Nov. 27	CI
Ocuphire Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Ocuphire Pharma, Inc. Announces Successful End-Of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy	Nov. 02	CI
Ocuphire Pharma Appoints George Magrath as Chief Executive	Nov. 01	MT
Ocuphire Pharma, Inc. Appoints George Magrath as Member of Board of Directors	Nov. 01	CI
Ocuphire Pharma, Inc. Announces Chief Executive Officer Changes	Nov. 01	CI
Viatris, Ocuphire Pharma Say US FDA Approves Eye Drops to Treat Pharmacologically-Induced Dilation of Pupils	23-09-27	MT

Chart Ocuphire Pharma, Inc.

Duration

Period

More charts

Company Profile

Ocuphire Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. The Companyâs lead retinal product candidate, APX3330, is a small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein). Ref1 is a regulator of transcription factors such as HIF-1Î± and NF-B. The Inhibiting REF-1 reduces levels of vascular endothelial growth factor (VEGF) and inflammatory cytokines which are known to play key roles in ocular angiogenesis and inflammation. APX3330 is an oral tablet to be administered twice per day for the treatment of DR. The Companyâs pipeline candidates include APX2009 and APX2014. The Company is initially pursuing APX3330 for the DR indication as first-line therapy and may explore opportunities for clinical benefit as monotherapy or adjunctive therapy for other retinal indications such as DME, wAMD, and GA.

Sector

Pharmaceuticals

Calendar

2024-07-11 - American Society of Retina Specialists Scientific Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Ocuphire Pharma, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.81 USD

Average target price

19.33 USD

Spread / Average Target

+968.14%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
OCUPHIRE PHARMA, INC.	-35.55%	46.92M
ELI LILLY AND COMPANY	+62.89%	841B
NOVO NORDISK A/S	+40.42%	625B
JOHNSON & JOHNSON	-3.96%	360B
MERCK & CO., INC.	+17.43%	327B
ABBVIE INC.	+10.46%	300B
ASTRAZENECA PLC	+15.66%	242B
NOVARTIS AG	+17.90%	227B
AMGEN INC.	+15.67%	174B
PFIZER, INC.	+0.82%	162B

Other Pharmaceuticals

Ocuphire Pharma, Inc.

Equities

OCUP

US67577R1023

Pharmaceuticals

Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy At Retina Meetings in June

EPS Revisions